Stock TYRA TYRA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tyra Biosciences, Inc.

Equities

TYRA

US90240B1061

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
17.85 USD -3.67% Intraday chart for Tyra Biosciences, Inc. +13.91% +28.88%
Mar. 20 HC Wainwright Adjusts Tyra Biosciences Price Target to $23 From $19, Maintains Buy Rating MT
Mar. 19 Tyra Biosciences Q4 Net Loss Widens MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Tyra Biosciences Price Target to $23 From $19, Maintains Buy Rating
MT
Tyra Biosciences Q4 Net Loss Widens
MT
Tyra Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
PR
Tyra Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Transcript : Tyra Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:00 AM
Tyra Biosciences to Present at Upcoming Investor Conferences
PR
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
PR
Tyra Biosciences, Inc. announced that it has received $200.006021 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC
CI
Wedbush Lifts Tyra Biosciences' PT to $28 From $27, Tweaks Financing Assumptions; Keeps Outperform Rating
MT
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care
MT
Tyra Biosciences Launches $200 Million Private Placement; Shares Rise
MT
Top Midday Gainers
MT
Tyra Biosciences Launches $200 Million Private Placement; Shares Rise
MT
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
PR
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for Potential Achondroplasia Treatment
MT
Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy
DJ
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
PR
Tyra Biosciences, Inc. Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TYRA Stock
  4. News Tyra Biosciences, Inc.